Supply and Distribution Agreement Sample Contracts

Kamada Ltd – SECOND ADDENDUM TO SUPPLY AND DISTRIBUTION AGREEMENT (February 27th, 2019)

This second addendum (the “Amendment”) to the Supply and Distribution Agreement dated July 18, 2011 (the “Agreement”) is made and entered into as of October 11, 2018, by and between Kamada Ltd. (“Kamada”), and Kedrion S.p.A.(“Kedrion”).

Aceto Corp – Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SUPPLY AND DISTRIBUTION AGREEMENT (November 9th, 2018)

Aurobindo Pharma Ltd., a company existing under the laws of India with its registered office at Plot No.2, Maitri Vihar, Ameerpet, Hyderabad-500038, India, (hereinafter referred to as “Aurobindo”),

Oncolytics Biotech Inc – LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENT (March 19th, 2018)

ONCOLYTICS BIOTECH (BARBADOS) INC., a corporation organized under the laws of Barbados, having its principal offices at 1st Floor, Hastings House, Balmoral Gap, Hastings, Christ Church, Barbados WI BB14034 (“Oncolytics”); and

Medicines Co /De – AMENDMENT NO. 2 TO THE SUPPLY AND DISTRIBUTION AGREEMENT (November 9th, 2017)

This Amendment No. 2 (this “Amendment”) to the Agreement (defined below) is entered into by and between The Medicines Company, a company with its principal offices located at 8 Sylvan Way, Parsippany, NJ 07054 (“Innovator”), and Sandoz Inc., a Colorado corporation with a corporate address at 100 College Road West, Princeton, NJ 08540 (“Sandoz”), and shall be effective as of the Amendment Effective Date (defined below). Innovator and Sandoz may hereafter be referred to collectively as the “Parties” and individually as a “Party”.

Oasmia Pharmaceutical AB – SUPPLY AND DISTRIBUTION AGREEMENT (October 31st, 2017)
Oasmia Pharmaceutical AB – SUPPLY AND DISTRIBUTION AGREEMENT (August 24th, 2017)
Elite Pharmaceuticals Inc /Nv/ – SUPPLY AND DISTRIBUTION AGREEMENT (June 14th, 2017)

This SUPPLY AND DISTRIBUTION AGREEMENT (the “Agreement”), dated May 4, 2017 (the “Effective Date”), is by and between Dr. Reddy’s Laboratories Inc., organized and existing under the laws of New Jersey having an office at 107 College Road East, Princeton, New Jersey 08540 ("DRL") and Mikah Pharma, LLC, organized and existing under the laws of the State of Delaware, having an office at 20 Kilmer Drive, Hillsborough, New Jersey 08844 (“Mikah”). DRL and Mikah are each a “Party” and together constitute the “Parties” under this Agreement.

Kadmon Holdings, Inc. – THIRD AMENDMENT TO SUPPLY AND DISTRIBUTION AGREEMENT (March 22nd, 2017)

This Third Amendment modifies the Supply and Distribution Agreement by and between Kadmon Pharmaceuticals, LLC, a Pennsylvania Limited Liability Company (“KADMON”), with its principal place of business at 119 Commonwealth Drive, Warrendale, PA 15086 and Camber Pharmaceuticals, Inc., a Delaware company (“CAMBER”), with its principal place of business at 1031 Centennial Avenue, Piscataway, NJ 08854, effective as of February 23, 2016 and amended on May 20, 2016 and August 23, 2016 (collectively, the “Agreement”).  Capitalized terms not otherwise defined herein have the meanings ascribed to them in the Agreement.

Kadmon Holdings, Inc. – SECOND AMENDMENT TO SUPPLY AND DISTRIBUTION AGREEMENT (March 22nd, 2017)

This Second Amendment modifies the Supply and Distribution Agreement by and between Kadmon Pharmaceuticals, LLC, a Pennsylvania Limited Liability Company (“KADMON”), with its principal place of business at 119 Commonwealth Drive, Warrendale, PA 15086 and Camber Pharmaceuticals, Inc., a Delaware company (“CAMBER”), with its principal place of business at 1031 Centennial Avenue, Piscataway, NJ 08854, effective as of February 23, 2016 and amended on May 20, 2016 (collectively, the “Agreement”).  Capitalized terms not otherwise defined herein have the meanings ascribed to them in the Agreement.

Kamada Ltd – 1ST ADDENDUM TO SUPPLY AND DISTRIBUTION AGREEMENT (March 1st, 2017)

This 1st Addendum to the Supply & Distribution Agreement signed by and between Kamada Ltd., ("Kamada") and Kedrion S.p.A., ("Kedrion") on 18 July, 2011 (the "Agreement") is entered into this 15th day of October 2016.

Kamada Ltd – FIFTH AMENDMENT TO THE EXCLUSIVE MANUFACTURING, SUPPLY AND DISTRIBUTION AGREEMENT (March 1st, 2017)

This FIFTH Amendment to the Exclusive Manufacturing, Supply and Distribution Agreement dated August 23rd, 2010 as amended on September 6th, 2012, May 14th, 2013,  February 15th, 2014, and August 25th, 2015, by and between Baxalta US Inc., now part of Shire, having a place of business at 1200 Lakeside Dr., Bannockburn, IL 60060 (hereinafter "Baxalta") and Kamada Ltd., having a place of business at Science Park, Kiryat Weizmann, 7 Sapir St., Ness-Ziona, 74036, Israel (hereinafter "Kamada") (the "Agreement") is entered into as of this 10th  day of August, 2016 (the "Effective Date").  Baxalta and Kamada shall collectively be referred to as the "Parties".

Trovagene, Inc. – Transforming Oncology With Precision Medicine Solutions Company Overview January 2017 Forward-looking statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts constitute “forward- looking statements” for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statem (January 9th, 2017)
Lantheus Holdings, Inc. – LANTHEUS HOLDINGS ANNOUNCES DIVESTITURE OF ITS AUSTRALIAN RADIOPHARMACY SERVICING BUSINESS AND ENTRY INTO LONG-TERM SUPPLY AND DISTRIBUTION AGREEMENT Transaction Simplifies Service and Distribution Model in Australia; Expands International Reach of Products (August 11th, 2016)

NORTH BILLERICA, Mass. (August 11, 2016) – Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced the sale of its radiopharmacy servicing business in Australia to Global Medical Solutions, Ltd. (“GMS”). As part of the transaction, LMI and GMS also entered into a long-term supply and distribution contract under which LMI will continue to supply GMS and its affiliates with LMI’s products on commercial terms and under which GMS has agreed to certain product purchase commitments.

Kadmon Holdings, LLC – confidential SUPPLY AND DISTRIBUTION AGREEMENT (June 10th, 2016)

This Supply and Distribution Agreement (“Agreement”) made effective as of February 23, 2016 (the “Effective Date”) is made between Kadmon Pharmaceuticals, LLC., a Pennsylvania Limited Liability Company (“KADMON”), with its principal place of business at 119 Commonwealth Drive, Warrendale, PA 15086 and Camber Pharmaceuticals, Inc., a Delaware company (“CAMBER”), with its principal place of business at 1031 Centennial Avenue, Piscataway, NJ 08854. CAMBER and KADMON are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Kadmon Holdings, LLC – AMENDMENT TO SUPPLY AND DISTRIBUTION AGREEMENT (June 10th, 2016)

This Amendment modifies the Supply and Distribution Agreement by and between Kadmon Pharmaceuticals, LLC, a Pennsylvania Limited Liability Company (“KADMON”), with its principal place of business at 119 Commonwealth Drive, Warrendale, PA 15086 and Camber Pharmaceuticals, Inc., a Delaware company (“CAMBER”), with its principal place of business at 1031 Centennial Avenue, Piscataway, NJ 08854, effective as of February 23, 2016 (the “Agreement”). Capitalized terms not otherwise defined herein have the meanings ascribed to them in the Agreement.

Kadmon Holdings, LLC – confidential SUPPLY AND DISTRIBUTION AGREEMENT (March 18th, 2016)

This Supply and Distribution Agreement (“Agreement”) made effective as of February 23, 2016 (the “Effective Date”) is made between Kadmon Pharmaceuticals, LLC., a Pennsylvania Limited Liability Company (“KADMON”), with its principal place of business at 119 Commonwealth Drive, Warrendale, PA 15086 and Camber Pharmaceuticals, Inc., a Delaware company (“CAMBER”), with its principal place of business at 1031 Centennial Avenue, Piscataway, NJ 08854. CAMBER and KADMON are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Kamada Ltd – FOURTH AMENDMENT TO THE EXCLUSIVE MANUFACTURING, SUPPLY AND DISTRIBUTION AGREEMENT (February 25th, 2016)

This FOURTH Amendment to the Exclusive Manufacturing, Supply and Distribution Agreement dated August 23rd, 2010 as amended on September 6th, 2012, May 14th, 2013, and February 15, 2014 by and between Baxalta US Inc., having a place of business at One Baxter Way, Westlake Village, California 91361 (hereinafter “Baxalta”) and Kamada Ltd., having a place of business at Science Park, Kiryat Weizmann, 7 Sapir St., Ness-Ziona, 74036, Israel (hereinafter “Kamada”) (the "Agreement") is entered into as of this 10th  day of August, 2015 (the "Effective Date").  Baxalta and Kamada shall collectively be referred to as the “Parties”.

Medicines Co /De – SUPPLY AND DISTRIBUTION AGREEMENT (November 9th, 2015)

This SUPPLY AND DISTRIBUTION AGREEMENT (“Agreement”), dated as of July 2, 2015, is made by and between The Medicines Company, a company with its principal offices located at 8 Sylvan Way, Parsippany, NJ 07054 (“Innovator”), and Sandoz Inc., a Colorado corporation with a corporate address at 100 College Road West, Princeton, NJ 08540 (“Sandoz”).

Kamada Ltd – THIRD AMENDMENT TO THE EXCLUSIVE MANUFACTURING, SUPPLY AND DISTRIBUTION AGREEMENT (April 28th, 2015)

This Third Amendment to the Exclusive Manufacturing, Supply and Distribution Agreement dated August 23rd, 2010 as amended on September 6th, 2012, and May 14th, 2013,  by and between Baxter Healthcare Corporation having a place of business at One Baxter Way, Westlake Village, California 91361 (hereinafter “Baxter”) and Kamada Ltd., having a place of business at Science Park, Kiryat Weizmann, 7 Sapir St., Ness-Ziona, 74036, Israel (hereinafter “Kamada”) (the "Agreement") is entered into as of this 15th day of February, 2014 (the "Effective Date").  Baxter and Kamada shall collectively be referred to as the “Parties”.

Nexvet Biopharma Plc – MASTER COLLABORATION, SUPPLY AND DISTRIBUTION AGREEMENT (December 30th, 2014)

VIRBAC, a company organized under the law of FRANCE, with registered office at 1ère avenue 2065 M – L.I.D., 06516, Carros, France - registered under number 417 350 311 RCS at Grasse, France, acting for itself and its Affiliates, herein duly represented by Christian Karst, Member of the Executive Board,

Millennium Healthcare Inc. – eWellness Corporation Distance Monitored Physical Therapy Programs EWELLNESS CORPORATION AND MILLENIUM HEALTHCARE, INC. SUPPLY AND DISTRIBUTION AGREEMENT (December 12th, 2014)

Supply and Distribution Agreement.   EWC hereby enters into a Supply and Distribution agreement with MHI for EWC’s Product(s) for use as described in Exhibit A in the assigned EWC Products Territory. Subject to the terms and conditions set forth herein, EWC grants to MHI, and MHI Hereby accepts, a limited, transferable right to use its best efforts as one of EWC’s partners to promote and use the EWC’s DMpt programs.

Millennium Healthcare Inc. – AMENDED AND RESTATED PURCHASE, SUPPLY AND DISTRIBUTION AGREEMENT (December 12th, 2014)

This AMENDED AND RESTATED PURCHASE, SUPPLY AND DISTRIBUTION AGREEMENT (this "Agreement"), dated as of October 31, 2013 (the "Effective Date"), by and between Millennium Medical Devices LLC, a New York limited liability company having an address at 400 Garden City Plaza, Suite 440, Garden City, New York 11530 ("Millennium"), and CDx Diagnostics Inc., a Delaware corporation with an address at 2 Executive Boulevard, Suffern, New York 10901 (the "Company").

Millennium Healthcare Inc. – MASTER PURCHASE, SUPPLY AND DISTRIBUTION AGREEMENT (December 12th, 2014)

This MASTER PURCHASE·, SUPPLY AND DISTRIBUTION AGREEMENT (this "Agreement"), dated as of May 1, 2013, by and between · Millennium Medical Devices LLC, a New York limited liability company having an address at 400 Garden City Plaza, Suite 440, Garden City, New York 11530 ("Millennium"), and Heart Smart Inc., ·a New York corporation with an address at 1160 Jericho Turnpike, Huntington, New York 11743 (the "Company").

Millennium Healthcare Inc. – PURCHASE, SUPPLY AND DISTRIBUTION AGREEMENT (December 12th, 2014)

This PURCHASE, SUPPLY AND DISTRIBUTION AGREEMENT (this "Agreement"), dated as of February 1, 2013 (the "Effective Date"), by and between Millennium Medical Devices LLC, a New York limited liability company having an address at 400 Garden City Plaza, Suite 440, Garden City, New York 11530 ("Millennium"), and CDx Diagnostics Inc., a Delaware corporation with an address at 2 Executive Boulevard, , Suffern, New York 10901 (the "Company").

Biolife Solutions Inc – SUPPLY AND DISTRIBUTION AGREEMENT (November 6th, 2014)

This Supply and Distribution Agreement (“Agreement”) is entered into as of September 29, 2014 (the “Effective Date”) by and between SAVSU Technologies, LLC, a Delaware limited liability company having its principal place of business at 1 High Country Road, Santa Fe, NM 87508 (“Seller”), and biologistex CCM, LLC, a Delaware limited liability company having its principal place of business at 3303 Monte Villa Parkway, Suite 310, Bothell WA 98021 USA (“Buyer”, and together with Seller, the “Parties”, and each, a “Party”).

Heska Corp – AMENDMENT TO SUPPLY AND DISTRIBUTION AGREEMENT (August 5th, 2014)

This Amendment, effective as of January 1, 2014 (the "Effective Date"), modifies the Supply and Distribution Agreement between Heska Corporation ("Heska") and Boule Medical AB ("Boule"), dated June 17, 2003, hereinafter referred to as "Amendment No. 9", as modified by Amendment Letter dated June 1, 2004 (hereinafter referred to as "Amendment No. 1"), Amendment Letter dated December 31, 2004 (hereinafter referred to as "Amendment No. 2"), Amendment Letter dated July 12, 2005 (hereinafter referred to as "Amendment No. 3"), Amendment Letter dated March 20, 2007 (hereinafter referred to as "Amendment No. 4"), Amendment Letter dated January 23, 2008 (hereinafter referred to as "Amendment No. 5"), Amendment to Supply and Distribution Agreement effective as of October 1, 2008 (hereinafter referred to as "Amendment No. 6"), Amendment to Supply and Distribution Agreement effective as of June 1, 2011 (hereinafter referred to as "Amendment No. 7") and Amendment to Supply and Distribution Agreemen

eWELLNESS HEALTHCARE Corp – EWELLNESS CORPORATION AND MILLENNIUM HEALTHCARE, INC. SUPPLY AND DISTRIBUTION AGREEMENT (June 25th, 2014)
EnerSys – EnerSys Announces Arbitration Ruling Related to Altergy Supply and Distribution Agreement (May 15th, 2014)

READING, Pa., May 14, 2014 -- EnerSys (NYSE: ENS), the global leader in stored energy solutions for industrial applications, announced today it has received the decision of an arbitration panel in the EnerSys Delaware Inc. v. Altergy Systems arbitration matter. This action was initiated by EnerSys Delaware Inc. (“EDI”), a wholly-owned subsidiary of EnerSys, in November 2012 to seek arbitration of claims relating to a Supply and Distribution Agreement (the “SDA”) with Altergy Systems (“Altergy”), as required by the SDA. Following unsuccessful attempts to resolve their disputes by mediation in July 2013, the parties moved forward with arbitration in August 2013, where each party asserted various claims against the other.

eWELLNESS HEALTHCARE Corp – FORM OF EWELLNESS CORPORATION AND MILLENIUM HEALTHCARE, INC. SUPPLY AND DISTRIBUTION AGREEMENT (May 6th, 2014)
Millennium Healthcare Inc. – PURCHASE, SUPPLY AND DISTRIBUTION AGREEMENT (March 7th, 2014)

This PURCHASE, SUPPLY AND DISTRIBUTION AGREEMENT (this "Agreement"), dated as of February 1, 2013 (the "Effective Date"), by and between Millennium Medical Devices LLC, a New York limited liability company having an address at 400 Garden City Plaza, Suite 440, Garden City, New York 11530 ("Millennium"), and CDx Diagnostics Inc., a Delaware corporation with an address at 2 Executive Boulevard, , Suffern, New York 10901 (the "Company").

Millennium Healthcare Inc. – EWELLNESS CORPORATION AND MILLENIUM HEALTHCARE, INC. SUPPLY AND DISTRIBUTION AGREEMENT (March 7th, 2014)
Millennium Healthcare Inc. – MASTER PURCHASE, SUPPLY AND DISTRIBUTION AGREEMENT (March 7th, 2014)

This MASTER PURCHASE·, SUPPLY AND DISTRIBUTION AGREEMENT (this "Agreement"), dated as of May 1, 2013, by and between · Millennium Medical Devices LLC, a New York limited liability company having an address at 400 Garden City Plaza, Suite 440, Garden City, New York 11530 ("Millennium"), and Heart Smart Inc., ·a New York corporation with an address at 1160 Jericho Turnpike, Huntington, New York 11743 (the "Company").

Eagle Pharmaceuticals, Inc. – SUPPLY AND DISTRIBUTION AGREEMENT (December 20th, 2013)

This SUPPLY AND DISTRIBUTION AGREEMENT (“Agreement”), dated as of January 28, 2013, is made by and between Eagle Pharmaceuticals, Inc., a Delaware corporation with its principal offices located at 470 Chestnut Ridge Road, Woodcliff Lake, New Jersey 07677 (“Eagle”), and Sandoz AG, a Swiss corporation with a corporate address at Lichtstraße 35, CH 4056 Basel, Switzerland (“Sandoz”).

Eagle Pharmaceuticals, Inc. – SUPPLY AND DISTRIBUTION AGREEMENT (December 17th, 2013)

This SUPPLY AND DISTRIBUTION AGREEMENT (“Agreement”), dated as of January 28, 2013, is made by and between Eagle Pharmaceuticals, Inc., a Delaware corporation with its principal offices located at 470 Chestnut Ridge Road, Woodcliff Lake, New Jersey 07677 (“Eagle”), and Sandoz AG, a Swiss corporation with a corporate address at Lichtstraße 35, CH 4056 Basel, Switzerland (“Sandoz”).

Millennium Healthcare Inc. – EWELLNESS CORPORATION AND MILLENIUM HEALTHCARE, INC. SUPPLY AND DISTRIBUTION AGREEMENT (December 6th, 2013)

Supply and Distribution Agreement.   EWC hereby enters into a Supply and Distribution agreement with MHI for EWC’s Product(s) for use as described in Exhibit A in the assigned EWC Products Territory. Subject to the terms and conditions set forth herein, EWC grants to MHI, and MHI Hereby accepts, a limited, transferable right to use its best efforts as one of EWC’s partners to promote and use the EWC’s DMpt programs.